Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk

Breast Cancer Research and Treatment
Christina JustenhovenHiltrud Brauch

Abstract

Organic anion transporter polypeptides (OATPs, SLCOs) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in breast tissues could impact breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of SLCO1A2 expression. We investigated 31 variants located in PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 for an association with breast cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based breast cancer case-control collection comprising 1,021 cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with breast cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 do not contribute to breast carcino...Continue Reading

References

Apr 18, 2002·Journal of the National Cancer Institute·T KeyUNKNOWN Endogenous Hormones and Breast Cancer Collaborative Group
Nov 19, 2003·Pflügers Archiv : European journal of physiology·Matthias A HedigerElspeth A Bruford
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Aug 26, 2004·The Journal of Pharmacology and Experimental Therapeutics·Takashi NozawaIkumi Tamai
Sep 10, 2005·European Journal of Epidemiology·Beate PeschThomas Brüning
Sep 12, 2007·Pharmaceutical Research·Guofeng You
Oct 9, 2007·Breast Cancer Research and Treatment·Christina JustenhovenHiltrud Brauch
Feb 5, 2008·Pharmacogenomics·Mikko Niemi
May 20, 2008·Expert Opinion on Drug Metabolism & Toxicology·Anne T NiesDietrich Keppler
Jul 25, 2008·The New England Journal of Medicine·UNKNOWN SEARCH Collaborative GroupR Collins
Aug 1, 2008·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·B Hagenbuch, C Gui
Mar 18, 2009·Pharmacogenomics·Ryan M FrankeAlex Sparreboom
Mar 31, 2009·Nature Genetics·Shahana AhmedDouglas F Easton
Sep 30, 2009·British Journal of Pharmacology·A Kalliokoski, M Niemi

❮ Previous
Next ❯

Citations

Feb 23, 2013·Journal of Drug Delivery·Veronika Buxhofer-AuschTheresia Thalhammer
Sep 21, 2013·Expert Opinion on Therapeutic Targets·Ioly Kotta-LoizouStamatios Theocharis
Aug 27, 2014·Biopharmaceutics & Drug Disposition·Takeo Nakanishi, Ikumi Tamai
Apr 10, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M Del ReR Danesi
Sep 13, 2016·Nuclear Receptor Research·Satyanarayana R PondugulaSridhar Mani
Feb 24, 2015·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Xuefeng ZhangHaitang Xie
Oct 21, 2020·Cells·Bradley A CreamerJeff L Staudinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.